NCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04852887 2026-03-03
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT02927912 2026-02-17
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04683679 2026-02-17
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04478279 2026-02-09
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
Phase 1/2 Active not recruiting
NCT00066690 2026-02-06
SOFT
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT03488693 2026-01-13
TAILOR RT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02912312 2026-01-07
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04616248 2026-01-07
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Phase 1 Active not recruiting